Quantcast
Home > Quotes > TENX

Tenax Therapeutics, Inc. Common Stock (TENX) Quote & Summary Data

TENX 
$1.25
*  
0.04
3.31%
Get TENX Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading TENX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
25.125
Today's High / Low
$ 1.2556 / $ 1.20
Share Volume
184,784
50 Day Avg. Daily Volume
835,487
Previous Close
$ 1.21
52 Week High / Low
$ 12.63 / $ 1.03
Market Cap
3,771,561
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.38

Intraday Chart

Shares Traded

Share Volume:
184,784
50 Day Avg. Daily Volume:
835,487

Trading Range

The current last sale of $1.25 is 21.36% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.2556 $ 12.63
 Low: $ 1.20 $ 1.03

Company Description (as filed with the SEC)

Tenax Therapeutics was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. Effective June 30, 2008, we changed the domiciliary state of the corporation to Delaware and changed the company name to Oxygen Biotherapeutics, Inc. On September 19, 2014, we changed the company name to Tenax Therapeutics, Inc. We are a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. On November 13, 2013, through our wholly owned subsidiary, Life Newco, Inc., or Life Newco, we acquired a license granting Life Newco an exclusive, sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the United States and Canada.  ... More ...  


Risk Grade

Where does TENX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.20
Open Date:
Feb. 15, 2019
Close Price:
$ 1.23
Close Date:
Feb. 15, 2019

Consensus Recommendation

Analyst Info